Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anticancer clinical efficiency and stochastic mechanisms of belinostat

1 Aug 2023

Abstract excerpt

Cancer progression is strongly affected by epigenetic events in addition to genetic modifications. One of the key elements in the epigenetic control of gene expression is histone modification through acetylation, which is regulated by the synergy between histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are thought to offer considerable potential for the development of anticancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to HIV/AIDS drug development and treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37541175
DOI: 10.1016/j.biopha.2023.115212

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticancer clinical efficiency and stochastic mechanisms of belinostatPMID 37541175Read ↗

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.Semantic proximity Read ↗

Histone deacetylase inhibitors in cancer therapy. A reviewSemantic proximity Read ↗

The pharmacoepigenetic paradigm in cancer treatmentSemantic proximity Read ↗

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsSemantic proximity Read ↗

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid TumorsSemantic proximity Read ↗

Histone Deacetylase Inhibitors for Peripheral T-cell Lymphomas: From Biology to Real-World TherapySemantic proximity Read ↗

Mechanisms of HDACs in cancer developmentSemantic proximity Read ↗

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid MalignanciesSemantic proximity Read ↗

Histone-Deacetylase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomasSemantic proximity Read ↗

HDAC Inhibitor Vorinostat and BET Inhibitor Plx51107 Epigenetic Agents’ Combined Treatments Exert a Therapeutic Approach Upon Acute Myeloid Leukemia Cell ModelSemantic proximity Read ↗

Histone deacetylase inhibitors: a patent review (2009 – 2011)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.